Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 (melatonin) for neurological symptoms in xeroderma pigmentosum (XP-2)
jRCTs051240228Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of melatonin in xeroderma pigmentosum (XP), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Change in neurological severity scale section 1 and Change in neurological severity scale section 3. Started Feb 2025; status: recruiting.
02
Drugs
melatonin
03
Conditions
xeroderma pigmentosum (XP)
Beyond the preview
Go deeper on jRCTs051240228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240228.